Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2001

View Archived Issues

Curis begins clinical evaluation of Vascugel in coronary artery disease

Atrix seeks FDA approval for one-month Leuprogel product

HspE7 granted orphan drug status from FDA for recurrent respiratory papillomatosis

Astra Zeneca seeks FDA approval for breast cancer treatment

Promising data reported from phase I trial of Esperion's ApoA-I Milano

Lumigan: a potent, long-acting and safe new IOP-lowering drug

Liposome-based formulation of mitoxantrone as a viable alternative to conventional drug

GPC Biotech reaches milestones in antimicrobial alliance with Byk Gulden

AACR news: novel fumagillin derivative CKD-732 as a component of combination chemotherapy

Shareholders overwhelmingly approve BioChem Pharma-Shire merger

Antiangiogenic therapies targeting both paracrine and autocrine VEGF signaling pathways

NeoTherapeutics begins phase II Parkinson's disease trial of Neotrofin

GlycoDesign expands GD-0039 clinical program

ImmunoGen and Raven to jointly develop novel antibody therapeutics for ovarian cancer

Research data on OSI-774 presented at AACR meeting

FDA grants priority review status for Entocort modified-release capsules

HGS initiates phase I trial of Albuferon as treatment for HCV

Autologous bone marrow cell implantation: a novel strategy for optimizing therapeutic angiogenesis

Raxofelast restores VEGF expression and stimulates healing, angiogenesis in diabetic mice

Design of new orally bioavailable factor Xa inhibitors reported at ACS

ACS news: A-292438 as a promising ETA-selective antagonist

DuPont R&D continues focus on potent, selective and orally active factor Xa inhibitors

Potent and selective 20-HETE synthase inhibitors under study at Taisho

New series of factor Xa inhibitors patented by Cor research group

Indole-based 5-HT2 receptor ligands described by Vernalis

Telik prepares novel glucose uptake promoters for use in type 2 diabetes

Angiogene claims compounds with the ability to damage newly formed vascular endothelium

Two new patents owned by Pharmacia cover CDK inhibitors

Nonpeptide inhibitors of VLA-4-mediated cell adhesion emerge from R&D at Biogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...